

## Leadership Connection 2018 (15-18 September)

### Anxiety, Depression, and Quality of Life in Patients With the Diagnosis of Metastatic Uveal Melanoma

**Regine Nshimiyimana, DNP, PharmB, FNP-BC, AGACNP-BC, OCN, AOCNP<sup>1</sup>**

Cathie E. Guzzetta, PhD, RN, FAAN<sup>2</sup>

Mary-Michael Brown, DNP, RN<sup>3</sup>

Qiuping Zhou, PhD, RN<sup>4</sup>

Jennifer M. Johnson, MD, PhD, FACP<sup>1</sup>

Takami Sato, MD, PhD<sup>1</sup>

Scott W. Keith, PhD<sup>5</sup>

*(1)Department of Medical Oncology, Thomas Jefferson University & Jefferson Health, Philadelphia, PA, USA*

*(2)The George Washington University, School of Nursing, Washington, DC, DC, USA*

*(3)Department of Nursing, MedStar Health, Columbia, MD, USA*

*(4)The George Washington University, School of Nursing, Ashburn, VA, USA*

*(5)Department of Biostatistics, Thomas Jefferson University & Jefferson Health, Philadelphia, PA, USA*

#### Background

Awareness of a patient's anxiety, depression, and quality of life (QOL) in those with metastatic uveal melanoma (MUM) can influence care that meets patients' bio-psycho-social-spiritual needs.

#### Objectives

The primary objective of this pilot study was to measure the level of anxiety, depression, and QOL in patients with MUM. The secondary objective was to explore potential differences in the levels of anxiety, depression, and QOL by gender, age range, time elapsed between the initial diagnosis of uveal melanoma and metastasis, and duration of illness since metastasis.

#### Research Questions

1. In patients with MUM aged 18 and older, what is the level of anxiety, depression, and perceived QOL?
2. How many patients with MUM had at least borderline anxiety (scores  $\geq 8$ ), at least borderline depression (scores  $\geq 8$ ), and a decrease in global QOL (scores  $< 7$ )?

#### Hypotheses

This pilot study was a hypothesis-generating study for a potential larger and powered study that would test the following research hypotheses:

In patients with MUM:

1. There is a difference between gender and scores of: anxiety, depression, and QOL.
2. There is a difference between age range and scores of: anxiety, depression, and QOL.
3. There is a difference between the time elapsed between the initial diagnosis of uveal melanoma and metastasis and: anxiety scores, depression scores, QOL scores.
4. There is a difference between the duration of illness since metastasis and: anxiety scores, depression scores, QOL scores.

#### Theoretical Foundation

The psychosocial oncology framework provides a useful model that supports the value of exploring the level of anxiety, depression, and QOL in patients with MUM as well as tailoring a psychosocial management plan to match patient's needs to improve QOL (Turnbull et al., 2012).

This framework provides 8 major domains which aim to raise awareness and understanding of psychosocial care (Domain A), provide standard of care for screening and management of psychosocial needs (Domain B), delineate expectation of health care providers in terms of education, training, and communication of psychosocial issues (Domain C), define patient and family education (Domain D), explain quality oversight and monitor progress of psychosocial services (Domain E), enlighten workforce competencies for cancer services (Domain F), standardize transdisciplinary classification for psychosocial health services (Domain G), and promote psychosocial research (Domain H) (Turnbull et al., 2012).

## **Methods Research Design**

A descriptive-comparative survey design was used in this research study.

## **Study Sample**

The target population was all patients with MUM, aged 18 years and older, residing in the United States, and receiving care at a Mid-Atlantic referral practice of MUM. There were 136 patients.

## **Sample Size**

In this convenience sampling, 70 patients with MUM presented at this institution during the period of September 1 - December 1, 2017. Patients who could not read the surveys were included and completed the survey with the assistance of the investigators who read questions to them. Patients who did not speak English were excluded from this study.

## **Setting**

The setting was a large teaching hospital in the Mid-Atlantic, a referral practice of MUM.

## **Instruments and Measurement**

The demographic data sheet, the hospital anxiety and depression scale (HADS), and the World Health Organization Quality of Life (WHOQOL)-BREF questionnaire were used to collect a one data collection point on the same day during the survey period. No identifiable information was collected on the survey. At the end of the survey, a handmade thank you gift was given to participants. Permission to use HADS and WHOQOL-BREF questionnaire were granted by GL Education Group Limited and World Health Organization, respectively.

## **Hospital Anxiety and Depression Scale**

The HADS encompasses seven questions for anxiety and seven questions for depression (Stern, 2014). Scores for each subscale are 0 to 21 and are 4-point Likert scale with a range of 0-3. The level of anxiety or depression is estimated to be normal (0-7), borderline abnormal (score 8-10), and abnormal (score 11-21) (Bjelland, Dahl, Haug, & Neckelmann, 2002; Zigmond & Snaith, 1983). A score of  $\geq 8$  for anxiety has a specificity of 0.78 and a sensitivity of 0.9 whereas the same score for depression has a specificity of 0.79 and a sensitivity of 0.83 (Bjelland et al., 2002). Thus, a score of  $\geq 8$  for anxiety or depression should alert for a thorough bio-psychosocial evaluation.

## **World Health Organization Quality of Life-BREF**

The WHOQOL-BREF is a 26-item version consisting of seven items in physical health (QOL domain 1), six items in psychological health (QOL domain 2), three items in social relationships (QOL domain 3), eight items in environmental health (QOL domain 4), and two items in global QOL and general health (WHO, 2004). Each item is Likert scaled from 1 to 5 on a response scale. Scores range from 7 to 35 in domain 1, from 6 to 30 in domain 2, from 3 to 15 in domain 3, from 8 to 40 in domain 4, and from 2 to 10 in global QOL (Skevington et al., 2004; WHO, 2004). A higher score in each domain corresponds to a better QOL (WHO, 2004).

### **Results Reliability testing**

In this study, a measure of the internal reliability of the HADS showed Cronbach's alpha of 0.81 for anxiety and 0.83 for depression. The internal reliability of the WHOQOL-BREF questionnaire showed Cronbach's alpha of 0.84 for domain 1, 0.89 for domain 2, 0.90 for domain 4, and 0.56 for global QOL. It also showed very low internal consistency between the 3 items in domain 3 (Cronbach's alpha of 0.004) due to item 21 asking "How satisfied are you with your sex life?" If this item was deleted, Cronbach's  $\alpha$  would have been 0.68 for domain 3.

### **Demographic and Clinical Characteristic of the Sample**

There were 136 eligible patients with MUM. Among them, 70 presented to this institution during the allotted three-month survey period and were offered to complete the survey. Among them, 65 completed the survey with a response rate of 93%. Of the total sample, the majority were female (56.9%, n=37), older than 60 years (55.4%, n=36), white (98.5%, n=64), had a college education or above (78.5%, n=51), non-employed (56.9%, n=37), married (80%, n=52), parents of children (83.1%, n=54), but did not have a child less than 18 years (73.8%, n=48).

The time to metastasis was <1 year in 10.8% (n=7), 1 year to <5 years in 61.5% (n=40), <5 years in 72.3% (n=47), and  $\geq$  5 years in 27.7% (n=18). The duration of illness since metastasis was <1 year in 29.2% (n=19), 1 year to <5 years in 55.4% (n=36), and  $\geq$  5 years in 15.4% (n=10).

### **Research Questions Results**

In our total sample, the mean anxiety score was  $6.05 \pm 3.64$ , the mean depression score was  $3.48 \pm 3.27$ , the mean domain 1 score was  $27.28 \pm 5.38$ , the mean domain 2 score was  $23.52 \pm 4.59$ , the mean domain 3 score was  $11.71 \pm 2.35$ , the mean domain 4 score was  $34.40 \pm 5.13$ , and the mean score for global QOL was  $7.22 \pm 1.57$ . Among respondents, 30.8% (n=20) had anxiety scores  $\geq 8$ , 13.8% (n=9) had depression scores  $\geq 8$ , and 32.3% (n=21) had global QOL scores <7 indicating at least borderline anxiety, at least borderline depression, and decreased QOL scores.

### **Hypotheses Testing Results**

Hypothesis testing 1 found no significant difference in anxiety, depression, and QOL scores by gender.

Hypothesis testing 2 revealed that participants aged 18 to  $\leq 60$  years had higher anxiety scores ( $7.52 \pm 3.65$ ) than participants > 60 years ( $4.86 \pm 3.21$ ;  $p=0.003$ ). Also, younger group had lower QOL domain 4 scores of environmental health ( $32.48 \pm 5.23$ ) than participants > 60 years ( $35.94 \pm 4.55$ ;  $p=0.006$ ). No significant differences were found in depression scores, QOL domain 1-3, or global QOL scores by age groups.

Hypothesis testing 3 found no significant differences in anxiety scores, depression scores, or QOL scores based on the time to metastasis.

Hypothesis testing 4 revealed significant difference in anxiety scores among the three groups by the duration of illness since metastasis ( $p=0.01$ ). Group variances were homogenous. The Least Significant Difference (LSD) Post hoc analysis revealed that anxiety scores were higher in the < 1 year group ( $7.79 \pm 3.72$ ) compared to the 1 year to <5 years group ( $5.75 \pm 3.45$ ;  $p=0.04$ ), and were higher in the < 1 year group ( $7.79 \pm 3.72$ ) compared to the  $\geq 5$  years group ( $3.80 \pm 2.78$ ;  $p=0.004$ ).

Moreover, our results showed difference in QOL domain 1 scores for physical health among the three groups ( $p=0.05$ ). LSD Post hoc analysis revealed that QOL domain 1 scores were only significantly higher in the < 1 year group ( $29.11 \pm 4.03$ ) compared to the 1 year to <5 years group ( $25.81 \pm 5.85$ ;  $p=0.03$ ). No significant differences were found in depression scores, QOL domain 2-4, or global QOL by the duration of illness since metastasis.

## Conclusions

Up to 30% of participants had at least borderline anxiety and a decreased global QOL while up to 10% had at least borderline depression. These findings support the integration of bio-psycho-social-spiritual practices in the care of patients with MUM.

---

### Title:

Anxiety, Depression, and Quality of Life in Patients With the Diagnosis of Metastatic Uveal Melanoma

### Keywords:

Anxiety, Metastatic Uveal Melanoma and Quality of Life

### References:

Bjelland, I., Dahl, A.A., Haug, T.T., Neckelmann, D. (2002). The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *Journal of Psychosomatic Research*, 52, 69–77. doi: 10.1016/S0022-3999(01)00296-3

GL Education Group. (n.d.). Hospital Anxiety and Depression Scale (HADS). Retrieved from <https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/>

Skevington, S. M., Lotfy, M., O'Connell, K. A., & WHOQOL Group. (2004). The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. *Quality of Life Research*, 13(2), 299-310.

Stern, A. F. (2014). The hospital anxiety and depression scale. *Occupational Medicine*, 64(5), 393-394. doi: 10.1093/occmed/kqu024

Turnbull, M. G. C., Baldassarre, F., Brown, P., Hatton-Bauer, J., Li, M., Green, E., & Lebel, S. (2012). Psychosocial care for cancer: a framework to guide practice, and actionable recommendations for Ontario. *Current Oncology*, 19(4), 209-216. doi: [10.3747/co.19.981](https://doi.org/10.3747/co.19.981)

World Health Organization. (2004). The World Health Organization quality of life (WHOQOL)-BREF. Retrieved from [http://www.who.int/substance\\_abuse/research\\_tools/en/english\\_whoqol.pdf](http://www.who.int/substance_abuse/research_tools/en/english_whoqol.pdf)

Zigmond A.S., & Snaith, R.P. (1983). The hospital anxiety and depression scale. *Acta Psychiatrica Scandinavica* 67, 361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x

### Abstract Summary:

Psychosocial needs of patients with metastatic uveal melanoma (MUM) have not been routinely assessed and addressed in clinical practice. Yet, awareness of patients' anxiety, depression, and perceived quality of life in those with MUM can influence care that meets patients' bio-psycho-social-spiritual needs.

**Content Outline:**

I. Background

II. Objectives

III. Research Questions

IV. Hypothesis

V. Theoretical Foundation

VI. Methods

1. Research Design
2. Study Sample
3. Sample Size
4. Setting
5. Instruments and Measurement

1. The demographic data sheet

2. The hospital anxiety and depression scale (HADS)

3. The World Health Organization Quality of Life (WHOQOL)-BREF questionnaire

VII. Results

1. Reliability testing
2. Demographic and Clinical Characteristic of the Sample
3. Research Questions Results
4. Hypotheses Testing Results

VIII. Conclusion

First Primary Presenting Author

**Primary Presenting Author**

Regine Nshimiyimana, DNP, PharmB, FNP-BC, AGACNP-BC, OCN, AOCNP

Thomas Jefferson University & Jefferson Health

Department of Medical Oncology

Nurse Practitioner and Adjunct Clinical Faculty

Philadelphia PA

USA

**Professional Experience:** May 2018 – Present -- Clinical Adjunct Faculty, Jefferson College of Nursing, Thomas Jefferson University, Philadelphia, PA Facilitate students' achievement of assessment and clinical skills. 2014 – Present -- Nurse Practitioner, Department of Medical Oncology, Jefferson Health, Philadelphia, PA Involved in the management of patients diagnosed with cancer who require inpatient care management. 2010 –2014 -- Staff Nurse, Oncology, Jefferson Health, Philadelphia, PA Involved in

the care of patients diagnosed with cancer. 2003- 2005 -- Head Pharmacist, Kigali Pharmacy, Kigali, Rwanda Managed operations of the pharmacy: dispensed medications, educated patients on the use of prescriptions, managed inventory, and reviewed supply orders.

**Author Summary:** Dr. Regine Nshimiyimana, born in Rwanda, is an American healthcare provider. She is certified as a family nurse practitioner (FNP-BC), an adult gerontology acute care nurse practitioner (AGACNP-BC), and an advanced oncology nurse practitioner (AOCNP). Dr. Nshimiyimana works as an oncology nurse practitioner and adjunct clinical faculty at Thomas Jefferson University & Jefferson Health in Philadelphia, PA. She has an interest in improving the quality of life of patients. Previously, she practiced as a pharmacist.

Second Author

Cathie E. Guzzetta, PhD, RN, FAAN

The George Washington University, School of Nursing

Clinical Professor

Washington, DC

USA

**Professional Experience:** Dr. Cathie Guzzetta is a Clinical Professor and DNP Clinical Research Project Coordinator at the George Washington University School of Nursing. Over the past 20 years, she has served as a hospital-based nursing research mentor for clinical nurses in various adult and pediatric medical centers. In this role, she has guided nurses in developing, conducting and disseminating the findings of their clinical nursing research studies. Dr. Guzzetta is best known for her work in cardiovascular, critical care and holistic nursing. She has served as Editor-in-Chief of Capsules & Comments in Critical Care Nursing and Co-Editor of the Alternative Therapies in Health and Medicine. She has written multiple articles and authored or co-authored 24 award-winning books including the Emergency Nurses Association's guidelines for family presence during CPR, "Presenting the Option for Family Presence". As a nursing research consultant, Dr. Guzzetta has mentored studies on family presence during cardiopulmonary resuscitation since 1994.

**Author Summary:** Dr. Regine Nshimiyimana is the primary author of the research study titled "Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma". She will present at Sigma Theta Tau International Leadership Connection.

Third Author

Mary-Michael Brown, DNP, RN

MedStar Health

Department of Nursing

Vice President, Nursing Practice Innovation, Adjunct Faculty

Columbia MD

USA

**Professional Experience:** Dr. Mary-Michael Brown is vice president of Nursing Practice Innovation for MedStar Health. Her responsibilities include creating and disseminating evidence-based clinical practice guidelines, providing oversight of the Nurses Improving Care for Healthsystem Elders (NICHE) and the National Database of Nursing Quality Indicators (NDNQI) programs, serving as an executive liaison to the MedStar Nursing Practice Council, and offering nursing input for system initiatives. Dr. Brown started her nursing career at MedStar Georgetown University Hospital in 1976, and subsequently practiced in progressive clinical roles at Boston University Medical Center, Scripps Mercy Hospital in San Diego, APACHE Medical, Bridge Medical, Alaris Medical, and Inova Alexandria Hospital. In 2007, she rejoined MedStar Health as director of Outcomes Measurement and then assistant vice president of Outcomes and Quality at MedStar Washington Hospital Center. In 2012, she assumed her current role in Corporate Nursing.

**Author Summary:** Dr. Regine Nshimiyimana is the primary author of the research study titled "Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma". She will present at Sigma Theta Tau International Leadership Connection.

Fourth Author  
Qiuping Zhou, PhD, RN  
The George Washington University, School of Nursing  
Assistant Professor  
Virginia Science and Technology Campus  
Ashburn VA  
USA

**Professional Experience:** Dr. Pearl Zhou is a research methodologist and Assistant Professor at the School of Nursing of The George Washington University. Her current research includes assessing the perceived benefits and burdens of cancer clinical trial participation and clinical trial retention, lifestyle behaviors among adults with prediabetes/diabetes, and health care for the underserved population. Dr. Zhou is actively engaged in research proposal development. She serves as a manuscript reviewer for several journals and a statistical reviewer for Nursing Research. Dr. Zhou's research findings have been published in numerous peer-reviewed journals.

**Author Summary:** Dr. Regine Nshimiyimana is the primary author of the research study titled "Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma". She will present at Sigma Theta Tau International Leadership Connection.

Fifth Author  
Jennifer M. Johnson, MD, PhD, FACP  
Thomas Jefferson University & Jefferson Health  
Department of Medical Oncology  
Assistant Professor  
Philadelphia PA  
USA

**Professional Experience:** Dr. Jennifer M. Johnson is a medical oncologist specializing in the treatment of head, neck, and lung cancer. She is an Assistant Professor and Associate Program Director for the Hematology and Medical Oncology Fellowship at the Sidney Kimmel Cancer Center at Thomas Jefferson University & Jefferson Health in Philadelphia, PA. Dr. Johnson has been at Jefferson for ten years.

**Author Summary:** Dr. Regine Nshimiyimana is the primary author of the research study titled "Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma". She will present at Sigma Theta Tau International Leadership Connection.

Sixth Author  
Takami Sato, MD, PhD  
Thomas Jefferson University & Jefferson Health  
Department of Medical Oncology  
Professor  
Philadelphia PA  
USA

**Professional Experience:** Dr. Takami Sato is a medical oncologist specializing in the treatment of melanoma. He is a professor and director for the Metastatic Uveal Melanoma Program at the Sidney Kimmel Cancer Center at Thomas Jefferson University & Jefferson Health in Philadelphia, PA. Dr. Sato was recognized as Best Doctors in America 2011, 2010, 2009, 2008, 2007, 2006, 2005 and America's Top Oncologists 2007

**Author Summary:** Dr. Regine Nshimiyimana is the primary author of the research study titled "Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma". She will present at Sigma Theta Tau International Leadership Connection.

Seventh Author

Scott W. Keith, PhD  
Thomas Jefferson University & Jefferson Health  
Department of Biostatistics  
Assistant Professor  
Philadelphia PA  
USA

**Professional Experience:** Dr. Scott W. Keith is an Assistant Professor in the department of Biostatistics at Thomas Jefferson University & Jefferson Health in Philadelphia, PA. His research interests include nonlinear modeling methodologies for binary and survival endpoints, pharmacoepidemiologic and epidemiologic research on cancer and hospitalization endpoints, and modeling the effects of obesity and weight loss on health outcomes including mortality, cardiovascular disease, diabetes, and headaches.

**Author Summary:** Dr. Regine Nshimiyimana is the primary author of the research study titled "Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma". She will present at Sigma Theta Tau International Leadership Connection.